240 related articles for article (PubMed ID: 14661056)
1. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Oncogene; 2004 Feb; 23(8):1539-48. PubMed ID: 14661056
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Clin Cancer Res; 2004 Apr; 10(7):2307-18. PubMed ID: 15073106
[TBL] [Abstract][Full Text] [Related]
3. Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein.
Bhutia YD; Hung SW; Krentz M; Patel D; Lovin D; Manoharan R; Thomson JM; Govindarajan R
PLoS One; 2013; 8(1):e53436. PubMed ID: 23335963
[TBL] [Abstract][Full Text] [Related]
4. Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2.
Tu M; Li H; Lv N; Xi C; Lu Z; Wei J; Chen J; Guo F; Jiang K; Song G; Gao W; Miao Y
Mol Cancer; 2017 Mar; 16(1):66. PubMed ID: 28327155
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies.
Réjiba S; Bigand C; Parmentier C; Hajri A
Neoplasia; 2009 Jul; 11(7):637-50. PubMed ID: 19568409
[TBL] [Abstract][Full Text] [Related]
6. Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
Xie H; Lin J; Thomas DG; Jiang W; Liu X
Int J Clin Exp Pathol; 2012; 5(4):347-55. PubMed ID: 22670179
[TBL] [Abstract][Full Text] [Related]
7. Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer.
Daylami R; Muilenburg DJ; Virudachalam S; Bold RJ
J Exp Clin Cancer Res; 2014 Dec; 33(1):102. PubMed ID: 25499121
[TBL] [Abstract][Full Text] [Related]
8. Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2).
Xia G; Wang H; Song Z; Meng Q; Huang X; Huang X
J Exp Clin Cancer Res; 2017 Aug; 36(1):107. PubMed ID: 28797284
[TBL] [Abstract][Full Text] [Related]
9. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
Vena F; Li Causi E; Rodriguez-Justo M; Goodstal S; Hagemann T; Hartley JA; Hochhauser D
Clin Cancer Res; 2015 Dec; 21(24):5563-77. PubMed ID: 26228206
[TBL] [Abstract][Full Text] [Related]
10. Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas.
Itoi T; Sofuni A; Fukushima N; Itokawa F; Tsuchiya T; Kurihara T; Moriyasu F; Tsuchida A; Kasuya K
J Gastroenterol; 2007 May; 42(5):389-94. PubMed ID: 17530364
[TBL] [Abstract][Full Text] [Related]
11. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Souzaki R; Tajiri T; Manabe T; Ohtsuka T; Tanaka M
Neoplasia; 2010 Oct; 12(10):807-17. PubMed ID: 20927319
[TBL] [Abstract][Full Text] [Related]
12. RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity.
Duxbury MS; Ito H; Benoit E; Zinner MJ; Ashley SW; Whang EE
Biochem Biophys Res Commun; 2003 Nov; 311(3):786-92. PubMed ID: 14623342
[TBL] [Abstract][Full Text] [Related]
13. MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy.
Lu H; Lu S; Yang D; Zhang L; Ye J; Li M; Hu W
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30777929
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma.
Chen D; Niu M; Jiao X; Zhang K; Liang J; Zhang D
Int J Mol Sci; 2012; 13(1):1186-1208. PubMed ID: 22312312
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells.
Lai IL; Chou CC; Lai PT; Fang CS; Shirley LA; Yan R; Mo X; Bloomston M; Kulp SK; Bekaii-Saab T; Chen CS
Carcinogenesis; 2014 Oct; 35(10):2203-13. PubMed ID: 24879635
[TBL] [Abstract][Full Text] [Related]
16. Ribonucleotide reductase M2 is a promising molecular target for the treatment of oral squamous cell carcinoma.
Iwamoto K; Nakashiro K; Tanaka H; Tokuzen N; Hamakawa H
Int J Oncol; 2015 May; 46(5):1971-7. PubMed ID: 25738429
[TBL] [Abstract][Full Text] [Related]
17. HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma.
Liau SS; Whang E
Clin Cancer Res; 2008 Mar; 14(5):1470-7. PubMed ID: 18316571
[TBL] [Abstract][Full Text] [Related]
18. Small interfering RNA (siRNA)-mediated silencing of the M2 subunit of ribonucleotide reductase: a novel therapeutic strategy in ovarian cancer.
Zhang M; Wang J; Yao R; Wang L
Int J Gynecol Cancer; 2013 May; 23(4):659-66. PubMed ID: 23466567
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.
Ohhashi S; Ohuchida K; Mizumoto K; Fujita H; Egami T; Yu J; Toma H; Sadatomi S; Nagai E; Tanaka M
Anticancer Res; 2008; 28(4B):2205-12. PubMed ID: 18751396
[TBL] [Abstract][Full Text] [Related]
20. ARID1A promotes chemosensitivity to gemcitabine in pancreatic cancer through epigenetic silencing of RRM2.
Li W; Chen Q; Gao W; Zeng H
Pharmazie; 2022 Sep; 77(7):224-229. PubMed ID: 36199183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]